PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Robin L. Jones, MD - Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science
Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView’s latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don’t miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders